The availability of faster test results expedites diagnosis and the initiation of treatment. Point-of-care testing has been developed to provide improvement in convenience, patient care, and turn-around time ( 1– 5). However, the discrepancy in hematocrit bias shows that accuracy established in one patient population cannot be automatically extrapolated to other patient populations, thus stressing the need for separate evaluation. The i-STAT analyzer is suitable for point-of-care testing of electrolytes and blood gases in critically ill patients, except for high pO 2. 0001) in the hematocrit range below 25% ( n = 11) using the i-STAT. In contrast to hematocrit measured during CPB, hematocrit using the non-CPB mode in the non-cardiac intensive care population showed an underestimation up to 2.2% ( p <. In the normal pO 2 range (10.6 < pO 2 <13.3 kPa), the performance of the i-STAT was comparable to the RapidLab. 0001 when 10 < pO 2 <30 kPa) and in the intensive care unit ( r = −0.61, p <. 03) and for pO 2 > 10 kPa during CPB ( r = −0.59, p <. A clear linear trend in deviation of i-STAT from RapidLab was noticed for pH during CPB ( r = 0.32, p =. Point-of-care electrolytes and blood gases had constant deviation, except for pH, pO 2, and hematocrit.
The agreement analysis for quantitative data was used to compare i-STAT to RapidLab for blood gas/electrolytes and for hematocrit with the Sysmex instrument. During a 3-month period, 48 blood samples from patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) and 42 blood samples from non-cardiac patients who needed intensive care treatment were analyzed on both the i-STAT analyzer (CPB and non-CPB mode, respectively) and our laboratory analyzers (RapidLab 865/Sysmex XE-2100 instrument). We therefore evaluated the analytical performance of the i-STAT point-of-care analyzer in two critically ill adult patient populations. This is especially true when biochemical parameters exceed the clinical reference range, in which acute and effective treatment is essential. Point-of-care analyzers may benefit therapeutic decision making by reducing turn-around-time for samples.
0 kommentar(er)
